The Problem of Aducanumab for the Treatment of Alzheimer Disease

被引：40

作者：

Alexander, G. Caleb ^{[1
,2
]}

Karlawish, Jason ^{[3
]}

机构：

[1] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA

[2] Johns Hopkins Sch Med, Baltimore, MD USA

[3] Univ Penn, Philadelphia, PA 19104 USA

来源：

ANNALS OF INTERNAL MEDICINE | 2021年 / 174卷 / 09期

关键词：

D O I：

10.7326/M21-2603

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1303 / +

页数：3

共 11 条

[1] Evaluation of Aducanumab for Alzheimer Disease Scientific Evidence and Regulatory Review Involving Efficacy, Safety, and Futility [J].

Alexander, G. Caleb ;

Emerson, Scott ;

Kesselheim, Aaron S. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2021, 325 (17) :1717-1718

[2]

Biogen

[3]

Eisai, ADUHELM ADUCANUMAB A

[4] Surrogate end points in clinical trials: Are we being misled? [J].

Fleming, TR ;

DeMets, DL .

ANNALS OF INTERNAL MEDICINE, 1996, 125 (07) :605-613

[5] Implications of FDA Approval of a First Disease-Modifying Therapy for a Neurodegenerative Disease on the Design of Subsequent Clinical Trials [J].

Grill, Joshua D. ;

Karlawish, Jason .

NEUROLOGY, 2021, 97 (10) :496-500

[6] Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval [J].

Gyawali, Bishal ;

Hey, Spencer Phillips ;

Kesselheim, Aaron S. .

JAMA INTERNAL MEDICINE, 2019, 179 (07) :906-913

[7]

Herper M, 2021, STAT NEWS

[8]

Krudys KM, 2020, M PER CENTR NERV SYS

[9]

Lin GA, 2021, ADUCANUMAB ALZHEIMER

[10] A critical appraisal of amyloid-βtargeting therapies for Alzheimer disease [J].

Panza, Francesco ;

Lozupone, Madia ;

Logroscino, Giancarlo ;

Imbimbo, Bruno P. .

NATURE REVIEWS NEUROLOGY, 2019, 15 (02) :73-88

← 1 2 →